Answers are grounded in this paper and cite their sources.
Oxidative stress and inflammation contribute to diabetes-related organ damage beyond hyperglycemia. Imeglimin and sodium-glucose cotransporter 2 inhibitors may modulate redox balance through distinct mitochondrial pathways, but their comparative effects on organ-level stress remain unclear. To compare the effects of imeglimin and empagliflozin on oxidative stress, inflammation, and subclinical organ stress markers in type 2 diabetes mellitus (T2DM). In this 24-week, prospective, randomized, open-label study, people with T2DM received imeglimin ( n = 34) or empagliflozin ( n = 42). Changes in urinary 8-hydroxy-2′-deoxyguanosine (u8-OHdG) and liver-type fatty acid-binding protein (L-FABP) were assessed as co-primary endpoints. Secondary endpoints included serum diacron-reactive oxygen metabolites (d-ROM), biological antioxidant potential (BAP), serum 8-OHdG (s8-OHdG), tumor necrosis factor receptors 1/2 (TNFR1/2), and organ stress markers: N-terminal pro-brain natriuretic peptide (NT-proBNP), Fibrosis-4 index (FIB-4), and cardio-ankle vascular index (CAVI). u8-OHdG levels increased significantly, while L-FABP levels were not significantly changed at 24 weeks, suggesting a systemic rather than renal oxidative response. Only empagliflozin improved FIB-4, NT-proBNP, and CAVI values. Both treatments reduced TNFR1/2 values and increased BAP values. In the empagliflozin group, univariate analysis showed that ΔFIB-4 was positively correlated with ΔTNFR1 and ΔTNFR2, while ΔNT-proBNP and ΔCAVI showed inverse trends with ΔBAP. Multivariate analysis identified changes in hemoglobin A1c and Δd-ROM as independent predictors of FIB-4 improvement, and empagliflozin use as an independent predictor of ΔCAVI. Both agents induced antioxidant and anti-inflammatory responses. In addition, empagliflozin improved cardiac, hepatic, and vascular stress markers, possibly through its antioxidant and anti-inflammatory effects. Japan Registry of Clinical Trials (registration number jRCT1061230069, date of registration October 24, 2023).
No takes yet. Share an insight, caveat, or question.
Otoda et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: